Related Experiment Video
Updated: Dec 22, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic
Mégane Vernon1,2, Bernard Lambert1,2,3, Matthieu Meryet-Figuière1,2
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
Abstract:
Novel therapeutic strategies are urgently required for the clinical management of chemoresistant ovarian carcinoma, which is the most lethal of the gynecologic malignancies. miRNAs hold promise because they play a critical role in determining the cell phenotype by regulating several hundreds of targets, which could constitute vulnerabilities of cancer cells. A combination of gain-of-function miRNA screening and real-time continuous cell monitoring allows the identification of miRNAs with robust cytotoxic effects in chemoresistant ovarian cancer cells. Focusing on miR-3622b-5p, we show that it induces apoptosis in several ovarian cancer cell lines by both directly targeting Bcl-xL and EGFR-mediating BIM upregulation. miR-3622b-5p also sensitizes cells to cisplatin by inhibiting Bcl-xL in ovarian cancer cell lines escaping BIM induction. miR-3622b-5p also exerts antimigratory capacities by targeting both LIMK1 and NOTCH1. These wide-ranging antitumor properties of miR-3622b-5p in ovarian cancer cells are mimicked by the associations of pharmacologic inhibitors targeting these proteins. The combination of an EGFR inhibitor together with a BH3-mimetic molecule induced a large decrease in cell viability in a panel of ovarian cancer cell lines and several ovarian patient-derived tumor organoids, suggesting the value of pursuing such a combination therapy in ovarian carcinoma. Altogether, our work highlights the potential of phenotype-based miRNA screening approaches to identify lethal interactions which might lead to new drug combinations and clinically applicable strategies.
Insights
Novel microRNAs (miRNAs) like miR-3622b-5p show potent anti-cancer effects against chemoresistant ovarian cancer. Combining targeted therapies mimicking these miRNA actions offers promising new treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian carcinoma is a leading cause of cancer-related death among gynecologic malignancies.
- Chemoresistance significantly limits treatment efficacy in advanced ovarian cancer.
- MicroRNAs (miRNAs) regulate gene expression and cellular phenotypes, offering potential therapeutic targets.
Purpose of the Study:
- To identify novel miRNAs with cytotoxic effects in chemoresistant ovarian cancer cells.
- To elucidate the molecular mechanisms of action for identified miRNAs.
- To explore potential combination therapies based on miRNA functions.
Main Methods:
- Phenotype-based miRNA screening combined with real-time cell monitoring.
- Functional assays to assess apoptosis, chemosensitization, and antimigratory effects.
- In vitro studies using ovarian cancer cell lines and patient-derived tumor organoids.
Main Results:
- miR-3622b-5p demonstrated significant cytotoxic effects by inducing apoptosis via Bcl-xL and EGFR/BIM pathways.
- miR-3622b-5p sensitized cells to cisplatin and inhibited migration by targeting LIMK1 and NOTCH1.
- Combination therapy with EGFR inhibitors and BH3-mimetics effectively reduced cell viability in ovarian cancer models.
Conclusions:
- miR-3622b-5p exhibits broad antitumor activities against ovarian cancer.
- Targeting pathways modulated by miR-3622b-5p with pharmacologic inhibitors shows therapeutic potential.
- This study validates phenotype-based miRNA screening for discovering novel therapeutic strategies and drug combinations in ovarian carcinoma.

